Top Health Tech Companies in Dublin (89)
InterSystems builds the software that makes complex systems work—reliably, securely, and at scale. For more than 45 years, we’ve been the information engine behind some of the world’s most mission-critical applications in healthcare, government, and business. Our data management, integration, and analytics technologies help organizations connect disparate systems, turn data into insight, and deliver better outcomes. From enabling interoperable healthcare and...
InterSystems's Top Stability & Growth Strengths
Profitability: The company is described as privately held, profitable, and debt-free, indicating a solid financial base. This positioning supports continued investment without reliance on external financing.
Strong Revenue Growth: Revenue is reported above $1 billion with indications of year-over-year increases into 2024 and sustained scale into FY2025, while cloud segments are noted as expanding strongly. These signals point to ongoing top-line momentum.
Market Expansion: Operations span 28 countries with 38 offices serving customers in 80+ countries, alongside recent moves such as a dedicated public-sector subsidiary and added international presence. This footprint suggests continued geographic and channel growth.
Optum, part of the UnitedHealth Group family of businesses, is a global organization that delivers care, aided by technology to help millions of people live healthier lives. The work you do with our team will directly improve health outcomes by connecting people with the care, pharmacy benefits, data and resources they need to feel their best. Here, you will find...
.jpg)
Optum's Top Stability & Growth Strengths
Strong Revenue Growth: Optum’s consolidated revenue expanded from $253.0B in 2024 to $270.6B in 2025, indicating continued top-line growth. Multi‑year reporting also highlights ongoing increases at the consolidated level even as segment performance diverges.
Diversified Revenue Streams: Performance is spread across three businesses, with Optum Rx delivering substantial gains, Optum Insight growing modestly, and Optum Health contracting. This mix shows pharmacy and technology services helping sustain overall scale despite softness in care delivery.
Cost & Operational Efficiency: Operating performance improved in 2026 as Optum’s operating income rose year over year to about $4B in Q2 alongside reported gains in technology and clinical operations. UnitedHealth also raised its 2026 adjusted EPS outlook, signaling confidence in execution.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Our products and services are designed to benefit people and improve their quality of life. At the same time, we aim to create value through innovation, growth and high earning power.
Bayer's Top Stability & Growth Strengths
Strong Market Position & Advantage: Bayer is positioned as a clear front-runner in Crop Science, with particularly strong standing when seeds/traits and digital agriculture are included alongside crop protection. It is also consistently placed within the top cohort globally in OTC/self-care, supporting leadership credibility across major end-markets.
Innovation-Driven Growth: Innovation activity is emphasized across seeds/traits, biologics, and digital farming, with multiple launches and late-stage programs cited as reinforcing Bayer’s pace-setting role in ag inputs. Newer pharmaceutical products like Nubeqa and Kerendia are described as ramping and helping offset headwinds from older brands.
Diversified Revenue Streams: The company operates across Crop Science, Pharmaceuticals, and Consumer Health, providing multiple earnings levers even when one segment faces cycle or lifecycle pressure. Incremental growth is highlighted as coming from Crop Science seeds/traits and newer Pharma assets while other categories remain flatter.
Kyan Health is an AI-powered enterprise solution that connects employee well-being with measurable business impact. Using predictive analytics, Kyan helps companies monitor and reduce risks like absenteeism, turnover, and presenteeism. With precision mental health interventions and real-time insights, Kyan proactively addresses challenges, fostering healthier, more engaged teams. Offering a global program that’s also locally relevant, Kyan provides the widest language...
Medserv are the leading provider of medical billing and practice management services to consultants, consultant groups and hospitals throughout Ireland and the UK. Our innovative Smartphone App allows consultants to quickly and securely send us patient information, whilst also keeping track of your claims and payments. Medserv strives to improve the management of your private practice through: - Reducing your practice administration -...
4G Clinical is driven by a single purpose: bring crucial medicines to those who need them, faster. 4G Clinical believes that the way to accelerate clinical research is by disrupting the way trials are executed. That’s why we have revolutionized RTSM (randomization and trial supply management) and supply forecasting capabilities and services from the ground up.
Uniphar is a diversified healthcare services organisation with activities in Ireland, UK, Europe, the USA and APAC
BVI® is refocusing the future of vision. As one of the fastest-growing, diversified surgical ophthalmic businesses in the world, our purpose-built portfolio of trusted brands includes: Beaver® (Knives and Blades), Visitec® (Cannulas), Malosa® (Single-Use Instruments), Vitreq® (Vitreoretinal Surgical Products) and PhysIOL® (Premium IOLs), and spans more than 90 countries. We’ve set our sights on touching the lives of millions of patients affected...
Thrive's mission is to unlock human potential by ending the stress and burnout epidemic. We offer companies and individuals sustainable, science-based solutions to enhance both mental and physical well-being and performance, purpose and relationship with technology. We are committed to accelerating this culture shift around the world. This page is meant to be a safe place for honest, respectful conversation, and...
Viatris is a global pharmaceutical company formed in 2020 through the combination of Mylan and Upjohn, a legacy division of Pfizer.
Viatris's Top Stability & Growth Strengths
Cost & Operational Efficiency: Cost-savings efforts are positioned as a concrete lever to support improved earnings and fund growth priorities, with an enterprise-wide program targeting substantial savings over multiple years. Guidance frames these actions as part of a broader move toward sustained revenue and earnings improvement beginning in 2026.
Resilient & Sustainable Growth: Growth is presented as re-emerging, with management guiding to a return to modest year-over-year revenue expansion in 2026 after a softer 2025. Improving quarterly trends exiting 2025 and a baseline of modest operational growth excluding divestitures support a narrative of stabilization.
Strong Market Position & Advantage: Scale and global reach are repeatedly highlighted as a stabilizing advantage, with broad geographic coverage and a large portfolio supporting access, supply reach, and competitive standing in off-patent medicines. The strategic shift toward complex generics and specialty brands is framed as reinforcing the company’s long-term positioning against pricing pressures.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
At Mallinckrodt, we use strategic vision and employee-driven momentum to pursue a powerful mission: Listening for needs and delivering solutions. As a leader in specialty pharmaceuticals, we develop, manufacture, market and distribute innovative treatments for underserved patient populations within neurology, rheumatology, hepatology, nephrology, pulmonology, ophthalmology, and oncology; immunotherapy and neonatal respiratory critical care therapies; analgesics; cultured skin substitutes and gastrointestinal...
At Sonder, we help organisations improve the wellbeing of their people and empower them to be at their best. We do this by providing leaders with a comprehensive care platform that delivers support through the right care, at the right time. Allowing people take control of their wellbeing in a way that suits them - on their terms, on their...
Thérapie Clinic is a medical-aesthetics provider offering laser hair removal, cosmetic injectables, body treatments, and advanced skin treatments. Founded in Ireland in 2002, it aims to make world-class aesthetic care accessible to everyone and help clients feel more confident in their own skin. Starting with one clinic, it has expanded across Europe and into New York, delivering personalized treatments through...
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of...
Bristol Myers Squibb's Top Stability & Growth Strengths
Strong Market Position & Advantage: Feedback suggests BMS holds a top‑tier global position with anchor franchises like Eliquis and Opdivo and a broad oncology footprint including cell therapies, reinforcing sustained competitive advantage.
Product Line Growth: Feedback suggests the company’s “growth portfolio” of newer medicines is expanding strongly, with assets such as Reblozyl, Breyanzi, Camzyos, Opdualag and Cobenfy helping to offset legacy declines.
Future-Ready Strategy: Feedback suggests recent acquisitions and collaborations (Karuna/Cobenfy, RayzeBio, Mirati, BioNTech) broaden modalities and late‑decade growth drivers, positioning the company to sustain leadership beyond current headwinds.
We are the creators of Complete Anatomy, the world’s most advanced 3D anatomy platform. Our revolutionary cloud-based platform allows users to investigate the details of the human anatomy in incredible 3D, transforming medical learning and practice across the world, leading the way in the production of ground-breaking 3D medical technology. Used by over 1,000,000 students, patients and professionals, our software...
LGC is a leading, global life science tools company, providing mission-critical components and solutions into high-growth application areas across the human healthcare and applied market segments. Its high quality product portfolio is comprised of mission-critical tools for genomic analysis and for quality assurance applications, which are typically embedded and recurring within our customers’ products and workflows and are valued for...
LGC's Top Stability & Growth Strengths
Strong Market Position & Advantage: Holding the UK’s National Measurement Laboratory designation and Government Chemist role, plus leading positions in reference materials, proficiency testing, and agrigenomics/genotyping, reinforces defensible niche leadership. Acquisitions and widespread adoption of technologies like KASP genotyping underscore recognized authority in core segments.
Strong Revenue Growth: Reported revenue increased year over year in FY25, reversing the prior year’s dip. Adjusted EBITDA also rose, indicating improved top-line momentum alongside better operating results.
Future-Ready Strategy: Large-scale site expansions (Toronto, Guildford, Berlin) and integration of recent acquisitions point to capacity build-out and a scale-focused operating model. A new CEO, business-unit consolidation, and an Innovation Hub signal intent to sustain growth through portfolio development and execution.
PTC is a patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for patients with rare and serious disease
At Output our mission is to make elite-level sports-science data simple and scalable. We specialise in providing high-value, low-burden data and insights to sports practitioners working at all levels of sport. Our single sensor V2 solution provides a 360 degree view of a weight-room and physio clinic with seamless athlete testing and tracking with a single stat of the art...
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion...
